AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,350,080 | -33.1% | 275,500 | -30.9% | 0.02% | -31.8% |
| Q2 2023 | $5,010,473 | -75.2% | 398,923 | -78.1% | 0.02% | -80.0% |
| Q1 2023 | $20,178,255 | -14.8% | 1,819,500 | -6.2% | 0.11% | -5.2% |
| Q4 2022 | $23,672,748 | -13.7% | 1,938,800 | -26.2% | 0.12% | -13.4% |
| Q3 2022 | $27,422,000 | +46.6% | 2,626,600 | +50.8% | 0.13% | +61.4% |
| Q2 2022 | $18,711,000 | +2.6% | 1,742,200 | -9.5% | 0.08% | +31.7% |
| Q1 2022 | $18,238,000 | -25.8% | 1,925,900 | -9.5% | 0.06% | +21.2% |
| Q4 2021 | $24,583,000 | +3916.8% | 2,128,400 | +3220.4% | 0.05% | +5100.0% |
| Q3 2021 | $612,000 | -72.2% | 64,100 | -71.9% | 0.00% | -80.0% |
| Q2 2021 | $2,201,000 | -88.0% | 228,300 | -87.7% | 0.01% | -88.9% |
| Q1 2021 | $18,391,000 | +288.3% | 1,861,400 | +282.8% | 0.04% | +125.0% |
| Q4 2019 | $4,736,000 | – | 486,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |